Overview

An Extension Study to a Clinical Study That Will Continue to Evalute the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antisychotic Medication

Status:
Not yet recruiting
Trial end date:
2025-01-10
Target enrollment:
Participant gender:
Summary
An Extension study to a clinical study that will continue to evalute the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their from their current antisychotic medication. This study will accept both male and female participants that have completed study SEP361-308. This study will be held in appoximately 24 study sites in North America. Particiaption in the study will be approximately up to 25 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion